OakChart

Stoke Therapeutics Inc

STOKHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 1:16 PM ET

27.30+0.09 (0.33%)
2026-11-11 19:17 CET
Market cap
1,779.71 USD m
Revenue, TTM
28.21 USD m
Net income, TTM
-243.20 USD m
Free cash flow, TTM
-215.72 USD m
EPS diluted, TTM
-3.80
P/E
-
Compare

Price

STOK against its 20, 50 and 200-day averages
2050200miss
25.0030.0035.001.7M3.4MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26STOKclose 27.3020-day 26.1550-day 26.59200-day 30.8227.3052w low

32.1% under the 52-week high of 40.22 on 10 Mar 2026. 52-week low 21.81 on 11 Nov 2025. Last 15 sessions, 16.0% high to low

Profile

STOK
52-week range, 30% of the way up
21.8140.22

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

IndexRUT
Employees170
IPOJun 19, 2019
Beta1.37
ATR, 14d1.25
Rel volume0.52
Short float19.78%
Insider own17.10%
Inst own111.61%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.79B
Enterprise Value1.47B
Income-243.20M
Sales28.21M
Book/sh5.44
Cash/sh4.88
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees170
IPOJun 19, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S63.29
P/B5.02
P/C5.59
P/FCF-
EV/EBITDA-
EV/Sales52.05
Quick Ratio7.24
Current Ratio7.24
Debt/Eq0.01
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.80
EPS next Y-4.09
EPS next Q-1.15
EPS this Y-3201.67%
EPS next Y-3.18%
EPS next 5Y-
EPS past 3/5Y64.49% 40.50%
Sales past 3/5Y145.89% -
EPS Y/Y TTM-634.38%
Sales Y/Y TTM-86.28%
EPS Q/Q-64.63%
Sales Q/Q5.86%
EarningsOct 29 AMC
EPS/Sales Surpr.-16.24% 37.06%

Ownership

Insider Own17.10%
Insider Trans-0.47%
Inst Own111.61%
Inst Trans9.64%
ROA-63.42%
ROE-73.62%
ROIC-68.84%
Gross Margin84.64%
Oper. Margin-913.12%
Profit Margin-862.07%
SMA204.39%
SMA502.65%
SMA200-11.44%
Trades-

Technical

Shs Outstand64.81M
Shs Float54.22M
Short Float19.78%
Short Ratio10.17
Short Interest10.72M
52W High40.22 -32.13%
52W Low21.81 25.17%
Volatility4.99% 5.00%
ATR (14)1.25
RSI (14)55.76
Beta1.37
Rel Volume0.52
Avg Volume1.05M
Volume326,595

Performance

Perf Week-0.55%
Perf Month21.33%
Perf Quarter-12.81%
Perf Half Y-13.88%
Perf YTD-13.99%
Perf Year8.72%
Perf 3Y540.81%
Perf 5Y-3.54%
Perf 10Y-
Recom1.00
Target Price46.38
Prev Close27.21
Price27.30
Change %0.33%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Aug 21, 2026ResumedJJP MorganOverweight$40+46.5%
Jul 13, 2026InitiatedGGoldmanBuy$44+61.2%
Feb 24, 2026InitiatedWWolfe ResearchOutperform$40+46.5%
Feb 05, 2026InitiatedGGuggenheimBuy$60+119.8%
Jan 05, 2026ResumedCChardan Capital MarketsBuy$35+28.2%
Jul 18, 2025InitiatedJJefferiesBuy$30+9.9%
Dec 20, 2024InitiatedCChardan Capital MarketsBuy$24-12.1%
Oct 14, 2024ResumedLLeerink PartnersOutperform$18-34.1%
Mar 26, 2024UpgradeTTD CowenMarket Perform → Outperform
Nov 20, 2023ResumedJJP MorganNeutral

Peers

Mkt cap
TickerCompanyMkt cap
PRAXPraxis Precision Medicines Inc9.76B
HRMYHarmony Biosciences Holdings Inc2.01B
XENEXenon Pharmaceuticals Inc4.09B
IONSIonis Pharmaceuticals Inc4.85B
JAZZJazz Pharmaceuticals plc15.76B
RAPPRapport Therapeutics Inc1.57B
WVEWave Life Sciences Inc682.21M
NGNENeurogene Inc527.46M
TSHATaysha Gene Therapies Inc1.38B
NBIXNeurocrine Biosciences Inc17.57B

Insider trading

latest 14 of 78
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Ticho BarryCHIEF MEDICAL OFFICERNov 02 '26Sale26.397,195189,91211,864Nov 04 04:05 PM
EDWARD KAYEFormer AffiliateOct 21 '26Proposed Sale25.681,496,04238,418,359Oct 21 04:42 PM
Allan JonathanGENERAL COUNSEL & CORP SECOct 02 '26Sale26.3362716,50920,598Oct 02 05:37 PM
Ticho BarryCHIEF MEDICAL OFFICEROct 01 '26Sale26.161,05127,49419,059Oct 02 05:35 PM
JONATHAN D ALLANOfficerOct 02 '26Proposed Sale26.0162716,308Oct 02 04:20 PM
Ticho BarryCHIEF MEDICAL OFFICERSep 01 '26Sale30.675,545170,06120,110Sep 03 04:17 PM
Ticho BarryCHIEF MEDICAL OFFICERAug 14 '26Option Exercise0.0010,000030,422Aug 18 08:29 PM
Ticho BarryCHIEF MEDICAL OFFICERAug 18 '26Sale32.034,767152,69025,655Aug 18 08:29 PM
Kaye Edward M. MDDirectorAug 14 '26Option Exercise0.0026,2500137,124Aug 18 08:28 PM
Kaye Edward M. MDDirectorAug 18 '26Sale32.0312,567402,528124,557Aug 18 08:28 PM
Allan JonathanGENERAL COUNSEL & CORP SECAug 14 '26Option Exercise0.006,000024,086Aug 18 08:27 PM
Allan JonathanGENERAL COUNSEL & CORP SECAug 18 '26Sale32.032,86191,63921,225Aug 18 08:27 PM
Ticho BarryCHIEF MEDICAL OFFICERAug 03 '26Sale29.047,176208,38520,422Aug 05 04:17 PM
BARUCH TICHOOfficerAug 03 '26Proposed Sale28.8620,967605,108Aug 03 04:48 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
DFASU.S. Small Cap Portfolio-ETF Class Shares-
TCAFT. Rowe Price Capital Appreciation Equity ETFAUM: 7.62B

News

latest 14 of 200
  • Stoke Therapeutics to Present at Upcoming Investor Conferences in November (Business Wire)
  • Stoke Therapeutics Misses On Launch-Driven Spending, But FDA Endpoint Deal Strengthens The Zorevunersen Case As Cash Runway Tightens (Earnings Whispers)
  • Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates (Business Wire)
  • Stoke's FDA Pre-NDA Outcome, Not Its Quarterly Loss, Is The Real Test For Shareholders (Earnings Whispers)
  • Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates (Business Wire)
  • Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
  • Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting (Business Wire)
  • Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization (Business Wire) -10.58%
  • Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
  • Stoke Therapeutics to Present at the Cantor Global Healthcare Conference (Business Wire)
  • Stoke Therapeutics and Biogen to present four-year zorevunersen data at epilepsy congress (InvestorsHub)
  • Stoke Therapeutics shares rise as JPMorgan starts coverage with Overweight rating (InvestorsHub)
  • Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
  • Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference (Business Wire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-29-1.080-0.929-1.08011.268.2114
2026Q22026-08-03-0.930-0.795-0.9339.334.8912
2026Q12026-05-07-0.790-0.808-0.7936.236.4812
2025Q42026-03-11-0.931-0.744-0.9921.325.8312
2025Q32025-11-04-0.650-0.568-0.65410.636.1611
2025Q22025-08-12-0.400-0.512-0.40213.828.9110
2025Q12025-05-131.9000.1091.900158.5729.3910
2024Q42025-03-18-0.180-0.528-0.18422.614.2810
2024Q32024-11-05-0.470-0.520-0.4694.893.838
2024Q22024-08-07-0.460-0.548-0.4614.833.709
2024Q12024-05-06-0.570-0.610-0.5704.223.269
2023Q42024-03-25-0.600-0.609-0.6002.803.669
2023Q32023-11-07-0.550-0.633-0.5543.313.648
2023Q22023-08-07-0.690-0.635-0.694-2.483.4410
2023Q12023-05-04-0.530-0.701-0.5305.153.0010
2022Q42023-03-06-0.650-0.713-0.6513.272.8610

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.800-1.873-1.7990.000.00
2020FY-1.560-1.534-1.5600.000.00
2021FY-2.340-2.299-2.3360.000.00
2022FY-2.600-2.661-2.59812.4111.70
2023FY-2.380-2.383-2.3808.789.53
2024FY-1.650-2.018-1.64836.5617.92
2025FY-0.0990.123-0.116184.37188.8
2026FY--3.962--35.47
2027FY--4.088--47.07
2028FY--2.632--136.36
2029FY--0.398--354.61
2030FY-1.696--611.55

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0313418.763.1917.50
2026Q4S2026-11-0213418.763.1917.50
2026Q4S2026-10-3013318.382.1017.50
2026Q4S2026-10-2913008.212.1017.50
2026Q4S2026-10-1813008.212.1017.50
2026Q4S2026-10-0713428.212.1017.50
2026Q4S2026-10-0213438.212.1017.50
2026Q4S2026-08-2013438.212.1017.50
2026Q4S2026-08-0412437.672.1017.50
2026Q4S2026-07-2210006.120.0019.00
2026Q4S2026-07-1010026.120.0019.00
2026Q4S2026-07-019026.800.0019.00
2026Q4S2026-06-259026.800.0019.00
2026Q4S2026-06-0110026.420.0019.00

Estimate history

EPS, annual-0.17-0.383-1.799-1.56-2.336-2.598-2.38-1.648-0.116-3.7957
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.469-0.1841.9-0.402-0.654-0.992-0.793-0.933-1.077
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000012.4058.7836.555184.4228.21
Period201720182019202020212022202320242025TTM
Sales, quarterly4.89422.614158.56913.81710.6321.4026.2299.32511.255
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual32.64532.67532.86236.57736.90239.4445.91854.03358.92264.814
Period201720182019202020212022202320242025MRQ
Shares, quarterly52.94154.03354.59654.72355.1258.92262.2462.40364.814
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue28.21184.4236.558.7812.400.000.000.000.00
Cost of Goods Sold Incl. D&A4.334.184.444.733.542.231.930.450.21
Gross Profit23.88180.2432.114.058.87-2.23-1.93-0.45-0.21
Selling, General and Administrative Excl. Other281.48200.83133.49118.82113.2383.8351.1235.2312.57
Research and Development188.94136.1586.9679.7676.2953.1931.3123.318.16
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-257.60-20.59-101.37-114.77-104.36-86.06-53.04-35.68-12.78
Interest Expense0.060.010.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.00--
Net Income Before Taxes-243.20-6.88-88.98-104.70-101.07-85.81-52.24-32.33-12.52
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-243.20-6.88-88.98-104.70-101.07-85.81-52.24-32.33-12.52
Net Income From Continuing Operations-243.20-6.88-88.98-104.70-101.07-85.81-52.24-32.33-12.52
Net Income-243.20-6.88-88.98-104.70-101.07-85.81-52.24-32.33-12.52
EPS (Recurring)-3.56-0.12-1.65-2.38-2.60-2.34-1.56-1.80-0.38
EPS (Basic, Before Extraordinaries)-3.80-0.12-1.65-2.38-2.60-2.34-1.56-1.80-0.38
EPS (Diluted)-3.80-0.12-1.65-2.38-2.60-2.34-1.56-1.80-0.38
EBITDA-253.27-16.41-96.93-110.04-100.82-83.83-51.12-35.23-12.57
Non-Operating Income (Expense)14.4613.7112.3910.073.290.260.803.350.26
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense40.4432.2427.4725.2622.8516.455.771.920.24
Price To Sales Ratio63.0110.1916.3026.3628.94----
Gross Margin84.6497.7387.8546.1471.50----
Operating Margin-913.12-11.16-277.31-1,307.21-841.24----
Net Margin-862.07-3.73-243.42-1,192.47-814.73----
Shares Outstanding64.8158.9254.0345.9239.4436.9036.5832.8632.67
Market Capitalization1,779.711,779.71584.23234.88363.95882.622,227.64926.91902.03

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue11.269.326.231.4010.6313.82158.5722.61
Cost of Goods Sold Incl. D&A1.091.141.051.050.991.061.081.11
Gross Profit10.168.195.180.359.6412.76157.4921.51
Selling, General and Administrative Excl. Other87.4873.6258.6061.7952.7340.0646.2535.16
Research and Development59.3849.0439.2341.2937.2525.4132.2022.90
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-77.31-65.43-53.42-61.44-43.09-27.30111.24-13.65
Interest Expense0.020.020.020.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-73.64-61.62-50.00-57.93-39.62-23.48114.16-10.48
Income Taxes0.000.000.000.00-1.280.001.280.00
Consolidated Net Income-73.64-61.62-50.00-57.93-38.35-23.48112.88-10.48
Net Income From Continuing Operations-73.64-61.62-50.00-57.93-38.35-23.48112.88-10.48
Net Income-73.64-61.62-50.00-57.93-38.35-23.48112.88-10.48
EPS (Recurring)-1.08-0.93-0.79-0.99-0.65-0.401.90-0.18
EPS (Basic, Before Extraordinaries)-1.08-0.93-0.79-0.99-0.65-0.401.95-0.18
EPS (Diluted)-1.08-0.93-0.79-0.99-0.65-0.401.90-0.18
EBITDA-76.22-64.29-52.37-60.38-42.10-26.24112.32-12.55
Non-Operating Income (Expense)3.693.833.443.513.473.822.923.17
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense11.0310.808.759.858.047.605.337.14
Price To Earnings Ratio---48.1027.8114.43--
Price To Sales Ratio63.0178.3064.0110.056.703.312.0717.21
Gross Margin90.3087.8083.1924.7590.7092.3499.3295.10
Operating Margin-686.94-701.65-857.57-4,382.24-405.30-197.5870.15-60.38
Net Margin-654.32-660.78-802.75-4,132.24-360.68-169.9671.19-46.36
Shares Outstanding64.8162.4062.2458.9255.1254.7254.6054.03
Market Capitalization1,779.712,037.861,925.951,812.901,287.74619.67359.62584.23

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments285.16216.97201.39229.59219.81287.31222.47105.401.80
Short Term Receivables7.910.700.060.590.130.010.280.200.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets12.6315.0813.8813.899.166.433.280.550.11
Total Current Assets305.70232.76215.34244.07229.10293.75226.03106.141.91
Net Property, Plant & Equipment6.258.2512.4311.439.083.792.511.190.47
Total Investments and Advances106.4930.550.570.570.570.200.200.200.06
Intangible Assets0.000.000.000.000.000.000.000.000.00
Other Assets0.000.000.000.000.120.180.000.000.00
Total Assets418.43271.56228.34256.07238.87297.93228.75107.542.44
Short Term Debt Incl. Current Port. of LT Debt3.012.322.062.361.510.000.000.003.00
Accounts Payable4.942.501.700.772.381.500.751.070.14
Other Current Liabilities49.9335.2427.0628.2713.259.933.351.400.57
Total Current Liabilities57.8840.0630.8231.3917.1411.434.102.473.71
Long Term Debt1.142.454.772.723.530.080.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities6.960.0333.1937.110.420.340.220.000.02
Total Liabilities65.9842.5368.7871.2221.0911.854.322.473.73
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.020.01
Common Equity352.46229.02159.56184.85217.78286.08224.43105.05-1.30
Total Shareholders Equity352.46229.02159.56184.85217.78286.08224.43105.07-1.29
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity352.46229.02159.56184.85217.78286.08224.43105.07-1.29
Total Liabilities & Stockholders Equity418.43271.56228.34256.07238.87297.93228.75107.542.44
Book Value Per Share5.984.243.474.695.907.826.833.21-0.04
Tangible Book Value Per Share5.984.243.474.695.907.826.833.21-0.04
Full-Time Employees1701281101171027956--
Price to Book Ratio5.002.521.351.784.077.924.153.86-
Return on Assets-2.00-35.60-43.23-40.84-31.97-19.84-19.22-22.77-
Return on Equity-2.37-45.80-60.80-50.20-34.06-20.47-19.62-24.13-
Return on Invested Capital-1.95-38.44-63.71-53.88-38.77-18.26-14.40-11.92-
Quick Ratio5.285.816.997.7713.3725.7155.1243.030.51
Current Ratio5.285.816.997.7713.3725.7155.1243.030.51

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-243.20-6.88-88.98-104.70-101.07-85.81-52.24-32.33-12.52
Depreciation4.334.184.444.733.542.231.930.450.21
Other Funds (Non Cash)38.9531.9525.8324.9322.6416.625.591.930.25
Funds from Operations-199.9129.24-58.71-75.04-74.89-66.95-44.73-29.95-12.06
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-10.3916.35-28.14-6.0343.020.052.33-1.101.09
Cash from Operating Activities-210.3145.59-86.85-81.07-31.87-66.91-42.40-31.05-10.96
Capital Expenditures-5.41-0.67-0.20-1.62-3.96-1.20-1.05-1.64-0.94
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.01
Purchase or Sale of Investments-6.15-186.14-107.27107.56-41.92-75.230.000.000.00
Purchase of Investments-202.19-322.72-167.270.00-201.32-87.230.000.000.00
Sale Or Maturity of Investments196.05136.5860.00107.56159.4012.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-11.56-186.81-107.47105.95-45.88-76.43-1.05-1.63-0.93
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock248.7497.39131.0953.0146.411.29108.29149.76115.64
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock248.7497.39131.0953.0146.411.29108.29149.76115.64
Proceedsfrom Stock Options234.1487.78128.8452.6445.910.51105.44149.45115.64
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.00-0.000.00-0.00-0.00
Other Financing Activities Uses0.000.000.000.000.00-0.000.00-0.00-0.00
Cash from Financing Activities248.7497.39131.0953.0146.411.28108.29149.76115.64
Net Change in Cash26.88-43.84-63.2377.89-31.34-142.0564.84117.07103.75
Free Cash Flow-215.7244.91-87.05-82.68-35.83-68.11-43.45-32.69-11.90
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00-
Price to Free Cash Flow-41.85-------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments319.19292.82343.55285.16248.31247.78
Short Term Receivables10.088.726.147.9110.841.62
Inventories0.000.000.000.000.000.00
Other Current Assets25.1521.0017.0012.6313.2920.57
Total Current Assets354.42322.54366.68305.70272.44269.97
Net Property, Plant & Equipment9.456.705.896.256.796.56
Total Investments and Advances42.8364.7370.71106.4981.04107.98
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets406.69393.97443.28418.43360.26384.51
Short Term Debt Incl. Current Port. of LT Debt1.241.842.433.012.912.30
Accounts Payable4.034.796.844.945.874.31
Other Current Liabilities43.7135.2931.5349.9332.9532.07
Total Current Liabilities48.9841.9340.8157.8841.7338.68
Long Term Debt0.680.840.991.141.871.25
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities4.455.656.606.968.569.63
Total Liabilities54.1048.4248.4065.9852.1649.56
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity352.59345.55394.88352.46308.11334.94
Total Shareholders Equity352.59345.55394.88352.46308.11334.94
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity352.59345.55394.88352.46308.11334.94
Total Liabilities & Stockholders Equity406.69393.97443.28418.43360.26384.51
Book Value Per Share5.445.546.345.985.596.12
Tangible Book Value Per Share5.445.546.345.985.596.12
Full-Time Employees---170--
Price to Book Ratio5.005.165.445.683.841.77
Return on Assets-63.42-53.41-39.94-2.0012.4115.16
Return on Equity-73.62-61.10-45.58-2.3715.0218.17
Return on Invested Capital-20.85-17.79-12.63-16.38-12.37-6.98
Quick Ratio7.247.698.995.286.536.98
Current Ratio7.247.698.995.286.536.98

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-73.64-61.62-50.00-57.93-38.35-23.48
Depreciation1.091.141.051.050.991.06
Other Funds (Non Cash)10.6810.438.399.458.118.12
Funds from Operations-61.87-50.05-40.57-47.43-29.25-14.30
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.82-6.54-20.0116.98-1.12-11.12
Cash from Operating Activities-62.69-56.59-60.58-30.45-30.37-25.42
Capital Expenditures-2.85-1.98-0.35-0.23-0.13-0.15
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-7.3610.9951.05-60.839.23-148.32
Purchase of Investments-58.01-36.11-9.85-98.23-23.93-181.55
Sale Or Maturity of Investments50.6547.1060.9037.4033.1533.23
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-10.219.0250.69-61.069.09-148.48
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock70.161.9184.3392.343.120.55
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock70.161.9184.3392.343.120.55
Proceedsfrom Stock Options65.690.0080.6687.780.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities70.161.9184.3392.343.120.55
Net Change in Cash-2.73-45.6674.440.83-18.15-173.34
Free Cash Flow-65.54-58.56-60.94-30.69-30.50-25.58
Price to Free Cash Flow---41.2626.3010.83

Revenue breakdown

Consolidation, Policy2024: -45.00K
License2024: 29.40M
Service2024: 7.20M
Total Pharmaceutical Preparations revenue2025: 184.42M
United States2024: 36.56M 2025: 184.42M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3019.78%10.7M54.2M1.04M
2026-10-1519.18%10.3M53.5M864.29K
2026-09-3021.51%11.5M53.5M852.89K
2026-09-1520.85%11.2M53.5M888.51K
2026-08-3120.94%11.2M53.5M863.62K
2026-08-1424.26%13.0M53.5M806.02K
2026-07-3129.57%15.8M53.5M723.22K
2026-07-1530.41%15.7M51.6M709.10K
2026-06-3026.68%13.9M52.1M689.81K
2026-06-1522.49%11.7M52.1M636.33K
2026-05-2922.81%11.2M49.2M702.80K
2026-05-1526.25%12.9M49.2M722.43K
2026-04-3026.62%13.0M48.9M736.05K
2026-04-1526.97%12.5M46.5M762.18K
2026-03-3127.81%12.8M46.1M809.29K
2026-03-1329.03%13.4M46.1M760.91K
2026-02-2727.86%12.4M44.5M760.73K
2026-02-1326.52%11.8M44.5M808.13K
2026-01-3024.14%11.2M46.3M938.78K
2026-01-1524.07%11.1M46.3M1.02M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call15.0010.0014.900.005.6920.000.000.975-0.0320.003
call17.508.0012.009.804.23413.000.000.968-0.0310.003
call20.005.009.807.633.72520.000.000.973-0.0180.003
call22.502.557.200.002.7260.000.000.734-0.3460.014
call25.001.003.903.501.6603100.000.662-0.2870.016
call30.000.001.000.640.90972.000.000.271-0.0720.014
call35.000.000.951.451.84223.000.000.236-0.1350.013
call40.000.001.150.052.3642730.000.199-0.1580.012
call45.000.000.952.462.78512.000.000.178-0.1730.011
call50.000.001.150.053.15014.000.000.164-0.1860.011
put15.000.004.900.102.1201.000.00-0.026-0.0300.003
put17.500.004.901.301.6382.000.00-0.033-0.0280.003
put20.000.000.100.151.07710,0220.00-0.027-0.0160.003
put22.500.004.900.951.97295.000.00-0.228-0.1390.013
put25.000.004.602.323.5006.000.00-0.334-0.2890.016
put30.001.255.504.652.29234.000.00-0.654-0.1010.016
put35.005.5010.007.702.75717.000.00-0.764-0.1320.013
put40.0010.6015.009.903.6901.000.00-0.801-0.1530.012
put45.0015.6020.000.004.1810.000.00-0.822-0.1680.011
put50.0020.1025.000.004.1550.000.00-0.836-0.1810.010

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-05SCHEDULE 13G/ASEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-298-KCurrent report2026-10-29SEC
2026-10-21144Filing for proposed sale of securities under Rule 144.SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-02SEC
2026-10-02144Filing for proposed sale of securities under Rule 144.SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-09-30SCHEDULE 13GSEC
2026-09-254Statement of changes in beneficial ownership of securities2026-09-23SEC
2026-09-253Initial statement of beneficial ownership of securities2026-09-23SEC
2026-09-258-KCurrent report2026-09-22SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-12SCHEDULE 13G/ASEC
2026-08-06SCHEDULE 13G/ASEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-03144Filing for proposed sale of securities under Rule 144.SEC
2026-08-038-KCurrent report2026-08-03SEC
2026-08-03424B5SEC
2026-08-03S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-038-KCurrent report2026-08-03SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-173Initial statement of beneficial ownership of securities2026-07-13SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1100189.91K1
2026-100044.00K2
2026-0900170.06K1
2026-0800855.24K4
2026-0700236.07K1
2026-060098.53K2
2026-050073.55K1
2026-040060.03K1
2026-03003.13M14
2026-020000
2026-010000
2025-12001.83M14
2025-11002.45M3

Institutional holders

Manager% owned
BlackRock, Inc.9.44%
RTW INVESTMENTS, LP9.03%
FMR LLC7.75%
Lynx1 Capital Management LP6.48%
Redmile Group, LLC6.34%
WELLINGTON MANAGEMENT GROUP LLP5.65%
MORGAN STANLEY5.54%
BAKER BROS. ADVISORS LP5.36%
TORONTO DOMINION BANK5.10%
STATE STREET CORP4.58%

Funds

Fund% owned
VANGUARD HEALTH CARE FUND3.63%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.03%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.53%
Select Biotechnology Portfolio2.30%
iShares Russell 2000 ETF2.27%
T. Rowe Price New Horizons Fund, Inc.1.17%
VANGUARD EXTENDED MARKET INDEX FUND1.03%
Select Health Care Portfolio0.97%
Fidelity Small Cap Index Fund0.97%
Fidelity Small Cap Growth Fund0.84%

OakChart. STOK. Cached 15 minutes.